Literature DB >> 25736302

Comparison of cytotoxic T lymphocyte responses against pancreatic cancer induced by dendritic cells transfected with total tumor RNA and fusion hybrided with tumor cell.

Jiang Chen1, Xiao-Zhong Guo2, Hong-Yu Li1, Di Wang1, Xiao-Dong Shao1.   

Abstract

Pancreatic cancer (PC) is a deadly human malignancy. Dendritic cell (DC)-based immunotherapy with whole tumor antigens demonstrates potential efficiency in cancer treatment. Tumor RNA and tumor fusion hybrid cells are sources of whole tumor antigens for preparing DC tumor vaccines. However, the efficacy of these sources in eliciting immune responses against PC has not yet to be directly compared. In the present study, patient-derived PC cells and DCs were fused (DC-tumor hybrids) and primary cultured PC cell-derived total RNA was electroporated into autologous DCs (DC-tumor RNA). The antitumor immune responses induced by DC-tumor hybrids and DC-tumor RNA were compared directly. The results showed that both RNA and hybrid methodologies could induce tumor-specific cytotoxic T lymphocyte (CTL) responses, but pulsing DCs with total tumor RNA could induce a higher frequency of activated CTLs and T-helper cells than fusing DCs with autologous tumor cells. In addition, DC-tumor RNA triggered stronger autologous tumor cell lysis than DC-tumor hybrids. It could be concluded that DCs pulsed with whole tumor RNA are superior to those fused with tumor cells in priming anti-PC CTL responses. Electroporation with total tumor RNA may be more suitable for DC-based PC vaccination.
© 2015 by the Society for Experimental Biology and Medicine.

Entities:  

Keywords:  Dendritic cell; cytotoxic T cell; hybrid; pancreatic cancer; tumor total RNA

Mesh:

Substances:

Year:  2015        PMID: 25736302      PMCID: PMC4935259          DOI: 10.1177/1535370215571884

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  40 in total

Review 1.  Pancreatic cancer.

Authors:  Manuel Hidalgo
Journal:  N Engl J Med       Date:  2010-04-29       Impact factor: 91.245

2.  Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.

Authors:  Jacalyn Rosenblatt; Baldev Vasir; Lynne Uhl; Simona Blotta; Claire Macnamara; Poorvi Somaiya; Zekui Wu; Robin Joyce; James D Levine; Dilani Dombagoda; Yan Emily Yuan; Karen Francoeur; Donna Fitzgerald; Paul Richardson; Edie Weller; Kenneth Anderson; Donald Kufe; Nikhil Munshi; David Avigan
Journal:  Blood       Date:  2010-10-28       Impact factor: 22.113

Review 3.  Dendritic cell-based cancer immunotherapies.

Authors:  Shin-ichiro Fujii; Takuya Takayama; Miki Asakura; Kaori Aki; Koji Fujimoto; Kanako Shimizu
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2009-05-29       Impact factor: 4.291

4.  A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocyte-derived dendritic cells: implications for immunotherapy.

Authors:  Andrew W Lee; Tuan Truong; Kara Bickham; Jean-Francois Fonteneau; Marie Larsson; Ida Da Silva; Selin Somersan; Elaine K Thomas; Nina Bhardwaj
Journal:  Vaccine       Date:  2002-12-19       Impact factor: 3.641

Review 5.  Manipulating immune cells for adoptive immunotherapy of cancer.

Authors:  Phillip K Darcy; Paul Neeson; Carmen S M Yong; Michael H Kershaw
Journal:  Curr Opin Immunol       Date:  2014-02-15       Impact factor: 7.486

6.  Dendritic cell/tumor hybrids enhances therapeutic efficacy against colorectal cancer liver metastasis in SCID mice.

Authors:  Feng Xu; Ying-Jiang Ye; Wei Liu; Meng Kong; Yu He; Shan Wang
Journal:  Scand J Gastroenterol       Date:  2010-06       Impact factor: 2.423

7.  Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.

Authors:  Toshiyasu Ojima; Makoto Iwahashi; Masaki Nakamura; Kenji Matsuda; Mikihito Nakamori; Kentaro Ueda; Teiji Naka; Koichiro Ishida; F James Primus; Hiroki Yamaue
Journal:  Int J Cancer       Date:  2007-02-01       Impact factor: 7.396

8.  Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.

Authors:  Noboru Ideno; Takao Ohtsuka; Hiroshi Kono; Kenji Fujiwara; Yasunori Oda; Shinichi Aishima; Tetsuhide Ito; Kousei Ishigami; Shoji Tokunaga; Kenoki Ohuchida; Shunichi Takahata; Masafumi Nakamura; Kazuhiro Mizumoto; Masao Tanaka
Journal:  Ann Surg       Date:  2013-07       Impact factor: 12.969

9.  Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry.

Authors:  Chanjuan Shi; Nipun Merchant; Guy Newsome; David M Goldenberg; David V Gold
Journal:  Arch Pathol Lab Med       Date:  2014-02       Impact factor: 5.534

10.  A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers.

Authors:  Jordan M Winter; Laura H Tang; David S Klimstra; Murray F Brennan; Jonathan R Brody; Flavio G Rocha; Xiaoyu Jia; Li-Xuan Qin; Michael I D'Angelica; Ronald P DeMatteo; Yuman Fong; William R Jarnagin; Eileen M O'Reilly; Peter J Allen
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

View more
  9 in total

1.  Efficacy of vaccination with tumor-exosome loaded dendritic cells combined with cytotoxic drug treatment in pancreatic cancer.

Authors:  Li Xiao; Ulrike Erb; Kun Zhao; Thilo Hackert; Margot Zöller
Journal:  Oncoimmunology       Date:  2017-04-20       Impact factor: 8.110

Review 2.  Advances in Human Dendritic Cell-Based Immunotherapy Against Gastrointestinal Cancer.

Authors:  Ling Ni
Journal:  Front Immunol       Date:  2022-05-10       Impact factor: 8.786

3.  Antigen-specific T cell response from dendritic cell vaccination using side population cell-associated antigens targets hepatocellular carcinoma.

Authors:  Xiao Li; Zhuochao Zhang; Guoying Lin; Yuanxing Gao; Zhen Yan; Heliang Yin; Bingyi Sun; Fangyuan Wang; Haijun Zhang; Hong Chen; Dayong Cao
Journal:  Tumour Biol       Date:  2016-03-07

4.  Dendritic cells engineered to secrete anti-DcR3 antibody augment cytotoxic T lymphocyte response against pancreatic cancer in vitro.

Authors:  Jiang Chen; Xiao-Zhong Guo; Hong-Yu Li; Jia-Jun Zhao; Wen-Da Xu
Journal:  World J Gastroenterol       Date:  2017-02-07       Impact factor: 5.742

5.  Combination epidermal growth factor receptor variant III peptide-pulsed dendritic cell vaccine with miR-326 results in enhanced killing on EGFRvIII-positive cells.

Authors:  Jianlong Li; Feng Wang; Guangzhi Wang; Ying Sun; Jinquan Cai; Xing Liu; Junhe Zhang; Xiaoyan Lu; Yongli Li; Meng Chen; Lingchao Chen; Chuanlu Jiang
Journal:  Oncotarget       Date:  2017-04-18

Review 6.  Clinical Outcomes of Specific Immunotherapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.

Authors:  Jiang Chen; Guo Xiao-Zhong; Xing-Shun Qi
Journal:  J Immunol Res       Date:  2017-02-07       Impact factor: 4.818

Review 7.  Cellular immunotherapies for cancer.

Authors:  Conall Hayes
Journal:  Ir J Med Sci       Date:  2020-07-01       Impact factor: 1.568

Review 8.  Targeting dendritic cells in pancreatic ductal adenocarcinoma.

Authors:  Anton Deicher; Roland Andersson; Bobby Tingstedt; Gert Lindell; Monika Bauden; Daniel Ansari
Journal:  Cancer Cell Int       Date:  2018-06-18       Impact factor: 5.722

Review 9.  Ribonucleic Acid Engineering of Dendritic Cells for Therapeutic Vaccination: Ready 'N Able to Improve Clinical Outcome?

Authors:  Yannick Willemen; Maarten Versteven; Marc Peeters; Zwi N Berneman; Evelien L J Smits
Journal:  Cancers (Basel)       Date:  2020-01-27       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.